血嗜酸性粒细胞与COPD三联及双联治疗反应:IMPACT试验分析
基于IMPACT试验的事后分析,评估血嗜酸性粒细胞计数和吸烟状态对COPD患者ICS治疗反应的影响。结果显示,含ICS方案减少中重度急性加重率的获益随血嗜酸性粒细胞计数升高而增大,吸烟状态可修饰该关系。提示血嗜酸性粒细胞计数和吸烟状态有助于优化ICS使用。
要点
- 血嗜酸性粒细胞计数越高,含ICS方案减少急性加重的获益越明显。
- former smokers较current smokers在任何嗜酸性粒细胞计数下对ICS反应更佳。
- 血嗜酸性粒细胞计数和吸烟状态可用于指导COPD患者ICS的个体化使用。
核心结论
- 含ICS方案减少中重度急性加重的获益随基线血嗜酸性粒细胞计数升高而增大。
- 吸烟状态可修饰疗效与血嗜酸性粒细胞计数之间的关系,former smokers对ICS反应更明显。
- 评估血嗜酸性粒细胞计数和吸烟状态有助于优化COPD患者的ICS使用。
研究设计与样本
- IMPACT为3期、随机、双盲、平行组、52周全球研究。
- 比较每日一次单吸入器三联疗法(fluticasone furoate-umeclidinium-vilanterol)与双联疗法(fluticasone furoate-vilanterol或umeclidinium-vilanterol)。
- 纳入中重度至极重度COPD且前一年至少一次中重度急性加重的患者。
- 采用分数多项式建模连续血嗜酸性粒细胞计数,负二项回归分析急性加重和肺炎,混合效应模型分析FEV1、SGRQ和TDI。
主要发现
- FEV1、TDI和SGRQ总分呈现类似趋势,但FEV1关系较弱。
- 三联 versus umeclidinium-vilanterol的 trough FEV1差异:<90 cells/μL时为40 mL(95%CI 10-70),≥310 cells/μL时为60 mL(20-100)。
关键数值与推荐
- trough FEV1差异(三联 versus umeclidinium-vilanterol):<90 cells/μL为40 mL(10-70),≥310 cells/μL为60 mL(20-100)。
临床怎么用
- 对COPD且有急性加重史的患者,可结合血嗜酸性粒细胞计数和吸烟状态评估ICS获益可能性。
- 血嗜酸性粒细胞计数较高者可能从含ICS方案中获得更大的急性加重减少获益。
- former smokers可能比current smokers在更低的嗜酸性粒细胞计数下即对ICS有较好反应。
局限性
- 本研究为IMPACT试验的事后分析。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have highlighted a relationship between reduction in rate of exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood eosinophil count in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial showed that once-daily single-inhaler triple therapy significantly reduced exacerbations versus dual therapies. Blood eosinophil counts and smoking status could be important modifiers of treatment response to ICS. We aimed to model these relationships and their interactions, including outcomes other than exacerbations. METHODS: IMPACT was a phase 3, randomised, double-blind, parallel-group, 52-week global study comparing once-daily single-inhaler triple therapy (fluticasone furoate-umeclidinium-vilanterol) with dual inhaled therapy (fluticasone furoate-vilanterol or umeclidinium-vilanterol). Eligible patients had moderate-to-very-severe COPD and at least one moderate or severe exacerbation in the previous year. We used fractional polynomials to model continuous blood eosinophil counts. We used negative binomial regression for numbers of moderate and severe exacerbations, severe exacerbations, and pneumonia. We modelled differences at week 52 in trough FEV1, St George's Respiratory Questionnaire (SGRQ) total score, and Transition Dyspnoea Index using repeated measurements mixed effect models. IMPACT was registered with ClinicalTrials.gov, number NCT02164513. FINDINGS: The magnitude of benefit of regimens containing ICS (fluticasone furoate-umeclidinium-vilanterol n=4151 and fluticasone furoate-vilanterol n=4134) in reducing rates of moderate and severe exacerbations increased in proportion with blood eosinophil count, compared with a non-ICS dual long-acting bronchodilator (umeclidinium-vilanterol n=2070). The moderate and severe exacerbation rate ratio for triple therapy versus umeclidinium-vilanterol was 0·88 (95% CI 0·74 to 1·04) at blood eosinophil count less than 90 cells per μL and 0·56 (0·47 to 0·66) at counts of 310 cells per μL or more; the corresponding rate ratio for fluticasone furoate-vilanterol versus umeclidinium-vilanterol was 1·09 (0·91 to 1·29) and 0·56 (0·47 to 0·66), respectively. Similar results were observed for FEV1, Transition Dyspnoea Index, and SGRQ total score; however, the relationship with FEV1 was less marked. At blood eosinophil counts less than 90 cells per μL and at counts of 310 cells per μL or more, the triple therapy versus umeclidinium-vilanterol treatment difference was 40 mL (95% CI 10 to 70) and 60 mL (20 to 100) for trough FEV1, -0·01 (-0·68 to 0·66) and 0·30 (-0·37 to 0·97) for Transition Dyspnoea Index score, and -0·01 (-1·81 to 1·78) and -2·78 (-4·64 to -0·92) for SGRQ total score, respectively. Smoking status modified the relationship between observed efficacy and blood eosinophil count for moderate or severe exacerbations, Transition Dyspnoea Index, and FEV1, with former smokers being more corticosteroid responsive at any eosinophil count than current smokers. INTERPRETATION: This analysis of the IMPACT trial shows that assessment of blood eosinophil count and smoking status has the potential to optimise ICS use in clinical practice in patients with COPD and a history of exacerbations. FUNDING: GlaxoSmithKline.
引用
- Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019. PMID: 31281061. doi:10.1016/S2213-2600(19)30190-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。